Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsingremitting multiple sclerosis

Authors
Category Primary study
ConferenceJournal of Neurology
Year 2012
This article has no abstract
Epistemonikos ID: 512b48d621b829f46cab9bc2e04ffbf4590f95c5
First added on: Apr 30, 2026